Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STN1010904 in Fuchs Endothelial Corneal Dystrophy
NCT05376176Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of STN1010904 in Fuchs endothelial corneal dystrophy (FECD) (3 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Best Corrected Visual Acuity with Contrast Level of 100% at 18 months, Best Corrected Visual Acuity with Contrast Level of 10% at 18 months and 1 more. Started May 2022; status: completed.
02
Drugs
STN1010904
03
Conditions
Fuchs endothelial corneal dystrophy (FECD)
Beyond the preview
Go deeper on NCT05376176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376176.